AbbVie again hikes guidance as it eyes neuro, obesity and PD-1xVEGF dealsnews2025-07-31T15:34:38+00:00July 31st, 2025|Endpoints News|
Bristol Myers raises revenue guidance for the year, prepares for major Cobenfy readoutsnews2025-07-31T15:16:10+00:00July 31st, 2025|Endpoints News|
Alnylam sharply raises sales projections for Amvuttra group on heels of new approvalnews2025-07-31T12:00:29+00:00July 31st, 2025|Endpoints News|
Moderna to cut 10% of workforce, CEO tells staff, as part of $1.5B savings effortnews2025-07-31T11:15:40+00:00July 31st, 2025|Endpoints News|
Lilly’s Mounjaro succeeds in cardiovascular outcomes trial, heads for expanded approvalnews2025-07-31T10:45:44+00:00July 31st, 2025|Endpoints News|
Despite Dupixent sales jump, Sanofi’s stock dips as profits fall shortnews2025-07-31T08:41:21+00:00July 31st, 2025|Endpoints News|
Teva expects to make Q3 decision on sale of API unit, CEO says news2025-07-30T19:32:59+00:00July 30th, 2025|Endpoints News|
Hospitals resume Sarepta’s gene therapy, but brace for coverage hurdlesnews2025-07-30T19:15:44+00:00July 30th, 2025|Endpoints News|
Prasad’s exit seen as positive for some biotechs, but uncertainty remainsnews2025-07-30T19:09:11+00:00July 30th, 2025|Endpoints News|
GSK reaffirms goal of bringing Blenrep to US, reports fail with TIM-3 inhibitornews2025-07-30T11:35:50+00:00July 30th, 2025|Endpoints News|
